

Figure S1. RAW264.7 cell flow cytometry gating strategy. (A) Proportion of CD86 and CD163 without antibody incubation. (B) Proportion of cells incubated with CD86 antibody alone. (C) Proportion of cells incubated with CD163 antibody alone. SSC-A, side scatter area; FSC-A, forward scatter area; FSC-H, forward scatter height; APC-A, allophycocyanin area; PE-A, phycoerythrin area.




Figure S2. THP-1 cell flow cytometry gating strategy. (A) Proportion of CD86 and CD163 without antibody incubation. (B) Proportion of cells incubated with CD86 antibody alone. (C) Proportion of cells incubated with CD163 antibody alone. SSC-A, side scatter area; FSC-A, forward scatter area; FSC-H, forward scatter height; APC-A, allophycocyanin area; PE-A, phycoerythrin area.




Figure S3. Levels of inflammatory factors in the serum of patients. Data are shown as mean \pm SEM; **P<0.01, *P<0.05 compared with the healthy group; ##P<0.01, #P<0.05 compared with the cirrhosis group.




Figure S4. Effect of DCA and HDCA on the viability of RAW264.7 and THP-1 cells. (A) Effect of DCA and HDCA on the viability of RAW264.7 cells. (B) Effect of DCA and HDCA on the viability of THP-1 cells. Data are expressed as mean \pm SEM (n=6); ##P<0.01, #P<0.05 compared with the DMSO group. DCA, deoxycholic acid; HDCA, hyodeoxycholic acid; PMA, fopferol 12-tetradecanoate 13-acetate; DMSO, dimethyl sulfoxide.




Figure S5. Analysis of iNOS/Arg-1 protein and mRNA expression ratios. (A) Analysis of iNOS to Arg-1 mRNA expression ratio in RAW 264.7 cells and THP-1 cells. (B) Ratio of protein levels of iNOS to Arg-1 in RAW 264.7 cells and THP-1 cells. Data are expressed as mean \pm SEM (n=3); **P<0.01, *P<0.05 compared with the control group; ##P<0.01 compared with the DCA or HDCA group; &&P<0.01, &P<0.05 compared with the LPS group. Arg-1, arginase-1; DCA, deoxycholic acid; HDCA, hyodeoxycholic acid; inducible nitric oxide synthase; LPS, lipopolysaccharide.

